A Retrospective Analysis of the Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine
If you agree to take part in this study, 1 blood sample (about 2 tablespoons) will be drawn
for use in genetic research.
If you are unable to provide a blood sample, researchers will collect leftover tissue
samples from your previously collected tumor tissue (from the time of the breast cancer
diagnosis). The tumor samples will be used for genetic research.
After the blood draw or tissue collection, your participation in this study will be over.
The blood samples for the genetic research will be stored at Myriad Laboratories. Before
your blood and/or tissue is sent to Myriad Laboratories for banking, your name and any
personal identifying information will be coded to protect your privacy. M. D. Anderson will
not have oversight of any leftover tissue and/or blood that will be banked by Myriad
Laboratories for additional research.
This is an investigational study. Up to 210 patients will take part in this study. All
will be enrolled at M. D. Anderson.
Observational Model: Case Control, Time Perspective: Retrospective
Incidence of DPYD variants in patients
Phuong K. Morrow, MD
M.D. Anderson Cancer Center
United States: Institutional Review Board
|UT MD Anderson Cancer Center||Houston, Texas 77030|